



**FOR IMMEDIATE RELEASE  
NEWS RELEASE**

TSX Venture:  
**AMF**

## **AMORFIX APPOINTS DR. HANS BLACK AS A NEW DIRECTOR**

TORONTO, ON, November 28, 2006 – Amorfix Life Sciences is pleased to announce the appointment of Dr. Hans Black to the company's Board of Directors. "We are extremely pleased to welcome Dr. Black to our Board," said Graham Strachan, Chair of the Board of Amorfix. "His substantial experience and leadership in the global financial industry coupled with strong corporate development background will be an asset as Amorfix continues to pursue its strategic objective of becoming a world leader in the prevention, diagnosis and treatment of misfolded-protein, neurodegenerative diseases."

Dr. Black received a Bachelor of Science from Union College in New York, law training in France and a Doctorate in Medicine from McGill University. He is a founder and CEO of Interinvest, a global money management firm which manages accounts for private and institutional clients who are serviced through offices in Boston and Montreal, and its affiliate offices in Bermuda, London and Zurich. He has been widely quoted, appearing in publications such as *Barron's*, *The International Herald Tribune*, *The Financial Times*, *Euromoney* and *The Wall Street Transcript* and appears frequently as a special guest on *The Nightly Business Report*.

Dr. Black is a member of the board of Abitibi-Consolidated Inc., Wi2Wi Inc., and Les Aliments Soyummi Inc. He serves on the Advisory Council of The Paul H. Nitze School of Advanced International Studies of Johns Hopkins University and the boards of the Montreal Symphony Orchestra, la Fondation Institut de Cardiologie de Montréal, Fondation Jeunesses Musicales du Canada, l'Orchestre de chambre I Musici de Montréal, Canadian Vocal Art Institute, The National Arts Centre and the Washington National Opera.

### **About Amorfix**

Amorfix is an emerging company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. Brain AMPs include infectious prions, which cause Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (mad cow disease), scrapie in sheep and the human form, variant Creutzfeldt-Jakob Disease (vCJD). A hallmark of Alzheimer's disease, Amyotrophic Lateral Sclerosis and Parkinson's disease is the accumulation of AMPs in neurons. Amorfix has developed a test procedure to diagnose AMP diseases using a routine blood sample and a novel therapeutic approach for treatment. The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for AMP diseases.

For further information, visit the website at [www.amorfix.com](http://www.amorfix.com) or contact:

Dr. George Adams, President and CEO  
Amorfix Life Sciences Ltd.  
416-482-3812  
[george.adams@amorfix.com](mailto:george.adams@amorfix.com)

James Parsons, CFO  
Amorfix Life Sciences Ltd.  
416-482-3814  
[james.parsons@amorfix.com](mailto:james.parsons@amorfix.com)

**The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.**